China Pharma Holdings Inc (CPHI) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
China Pharma Holdings Inc stock (CPHI) is currently trading at $0.59. China Pharma Holdings Inc PS ratio (Price-to-Sales) is 0.67. Analyst consensus price target for CPHI is $3.00. WallStSmart rates CPHI as Underperform.
- CPHI PE ratio analysis and historical PE chart
- CPHI PS ratio (Price-to-Sales) history and trend
- CPHI intrinsic value — DCF, Graham Number, EPV models
- CPHI stock price prediction 2025 2026 2027 2028 2029 2030
- CPHI fair value vs current price
- CPHI insider transactions and insider buying
- Is CPHI undervalued or overvalued?
- China Pharma Holdings Inc financial analysis — revenue, earnings, cash flow
- CPHI Piotroski F-Score and Altman Z-Score
- CPHI analyst price target and Smart Rating
China Pharma Holdings Inc
📊 No data available
Try selecting a different time range
Smart Analysis
China Pharma Holdings Inc (CPHI) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, price/sales, price/book. Concerns around market cap and return on equity. Mixed signals suggest waiting for clearer direction before acting.
China Pharma Holdings Inc (CPHI) Key Strengths (3)
Growing significantly faster than its price suggests
Paying less than $1 for every $1 of annual revenue
Trading below book value, meaning the market prices it less than net assets
Supporting Valuation Data
China Pharma Holdings Inc (CPHI) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very low institutional interest at 3.64%
Micro-cap company with very limited liquidity and high volatility
Solid revenue growth at 10.90% per year
China Pharma Holdings Inc (CPHI) Detailed Analysis Report
Overall Assessment
This company scores 45/100 in our Smart Analysis, earning a D grade. Out of 9 metrics analyzed, 3 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio, Price/Sales, Price/Book. Valuation metrics including PEG Ratio (0.16), Price/Sales (0.67), Price/Book (0.33) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Growth concerns include Revenue Growth at 10.90%, which may limit upside. Profitability pressure is visible in Return on Equity at -52.70%, Operating Margin at -48.90%, Profit Margin at -83.20%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -52.70% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 10.90% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CPHI Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CPHI's Price-to-Sales ratio of 0.67x trades at a deep discount to its historical average of 13.21x (90th percentile). The current valuation is 100% below its historical high of 318.14x set in Dec 2006, and 6590% above its historical low of 0.01x in Dec 2012.
Compare CPHI with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for China Pharma Holdings Inc (CPHI) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
China Pharma Holdings Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 4M with 11% growth year-over-year. The company is currently unprofitable, posting a -83.2% profit margin.
Key Findings
The company is unprofitable with a -83.2% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -237,600, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact China Pharma Holdings Inc.
Bottom Line
China Pharma Holdings Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About China Pharma Holdings Inc(CPHI)
NYSE MKT
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
China
China Pharma Holdings, Inc. develops, manufactures and markets generic and branded pharmaceutical and biochemical products primarily for hospitals and private retailers in the People's Republic of China. The company is headquartered in Haikou, the People's Republic of China.